Participants 54 118 3
patients with hormone receptor-positive metastatic breast cancer
Participants 436 640 6
Patients with newly metastatic disease or recurred after adjuvant tamoxifen (stratum 1), or recurred during/after adjuvant aromatase inhibitor (AI) or after failed first-line AI (stratum 2), were eligible
